How Recent Data Impacts Pancreatic Cancer Management

Integrity CE

M. Pishvaian

ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Pract…

2024 ESMO Annual Meeting Insights Hub

H. Babiker

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

2024 ASCO® Annual Meeting Insights Hub

E. Dotan

Updates in Perioperative Therapy of Pancreatic Cancer

Horizon CME

P. Philip

ASCO® 2024 Summary: "Advancing GI Cancer Treatment - The Clinical Ut…

2024 ASCO® Annual Meeting Insights Hub

S. Cohen

NORPACT-1 Trial Updates: Neoadjuvant FOLFIRINOX vs. Upfront Surgery …

Yale Cancer Center

J. Lacy

Clinical Takeaways in From Recent Key Trials in Pancreatic Cancer

Hani Babiker

Neoadjuvant IO in MSI-High GI Cancers: Special Focus on the DREAM GI…

Aditya Shreenivas

S. Chakrabarti

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Integrity CE

W. Burns

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

2024 ASCO® Annual Meeting Insights Hub

J. Knox

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

ecancer

J. Knox

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

Insights from 2024 ESMO GI Annual Meeting

T. Seufferlein

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

UCLA Health

Z. Wainberg

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 …

Yale Cancer Center

J. Lacy

Updates in Nonmetastatic Upper-GI Adenocarcinoma

Integrity CE

J. Hernandez

ASCO® 2024 Insights: "Efficacy, Safety, and PD of CM24 With Nivo & C…

2024 ASCO® Annual Meeting Insights Hub

T. Macarulla

Precision Medicine in GI Cancers

Fred Hutchinson Cancer Center

D. Zhen

Year in Review: Pancreatic Cancers

OncoAlert

M. Lewis

FDA Approval of Liposomal Irinotecan/NALIRIFOX in 1L Metastatic Panc…

Shubham Pant

Selecting Patients Wisely for Neoadjuvant Therapy in Pancreatic and …

ecancer

S. Shrikhande